Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493800 | 1.00 | FLT3 (0.61) | FLT3MAOBCA12CA2CA3 | |
| SCHEMBL11453883 | 0.89 | ALDH1A1 (0.54) | FLT3MAOBCA12CA2CA3 | |
| SCHEMBL28367859 | 0.88 | CYP1A2 (0.50) | FLT3MAOBCA12CA2CA3 | |
| Hydrochloric Acid SCHEMBL27448782 | 0.88 | FLT3 (0.54) | FLT3MAOBCA12CA2CA3 | |
| SCHEMBL25777700 | 0.86 | CA12 (0.59) | MAOBCA12CA2CA3CA4 | |
| SCHEMBL1066982 | 0.86 | TAS1R3 (0.56) | MAOBCA12CA2CA3CA4 | |
| SCHEMBL1473963 | 0.85 | MAOB (0.68) | FLT3MAOBCA12CA2CA3 | |
| SCHEMBL10396247 | 0.84 | CA12 (0.54) | MAOBCA12CA2CA3CA4 | |
| SCHEMBL2084419 | 0.84 | PIM1 (0.60) | MAOBCA12CA2CA3CA4 | |
| SCHEMBL10395770 | 0.84 | CA12 (0.56) | MAOBCA12CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118813733-A | Biocatalysis method for preparing vilazodone intermediate | 广东东阳光药业股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| JP-8291161-A | — | — | None | — | — | JP | disclosed |
| CN-122036587-A | Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction | 暨南大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12612389-B2 | Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2026-04-28 | — | — | US | disclosed |
| WO-2024238406-A1 | FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118813733-A | Biocatalysis method for preparing vilazodone intermediate | 广东东阳光药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118813733-A | Biocatalysis method for preparing vilazodone intermediate | 广东东阳光药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-114206857-B | Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions comprising the same | 韩国生命工学研究院 | 2024-09-06 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5723614-A | Benzofurans | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-03 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| EP-0648767-B1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GMBH (DE) | 1997-05-28 | — | — | EP | disclosed |
| JP-H08291161-A | BENZOFURAN COMPOUND | MERCK PATENT GMBH | 1996-11-05 | — | — | JP | disclosed |
| US-5532241-A | Piperidines and piperazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0648767-A1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GmbH (DE) | 1995-04-19 | — | — | EP | disclosed |
| EP-0586254-A1 | Furanoindoline derivatives and their use as antitumor agents | ELI LILLY AND COMPANY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5248691-A | Antitumor agent | ELI LILLY AND COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | RELA, NFKBIA, IKBKG | FLT3 2138/4885MAOB 3098/4885CA12 4088/4885 |
| US-12612389-B2 | Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same | TUBB3, TUBA1C, ACIN1 | FLT3 3902/4885MAOB 3406/4885CA12 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.